Excel Industries Q1FY27: consolidated PAT down 13% YoY to ₹29.5 Cr, core margins hold

Excel Industries reported consolidated Q1 FY27 revenue of ₹293.83 Cr, down 5.1% YoY (up 4.5% QoQ), and consolidated PAT of ₹29.47 Cr, down 12.7% YoY (up 139.9% QoQ), with EPS of ₹23.44 against ₹26.86 a year ago. Standalone PAT of ₹29.11 Cr (EPS ₹23.16) tracked closely with the consolidated number, so there is no material divergence between the two bases this quarter.

The margin picture is mixed and worth separating: core operating margin (EBIT excluding other income, as a share of revenue) actually expanded to about 14.4% from 13.6% a year ago and 7.8% last quarter, meaning the underlying chemicals business held up despite the revenue dip. But net profit margin compressed to 9.8% from 10.5% YoY because other income fell to ₹6.71 Cr from ₹12.21 Cr a year earlier — a ~45% YoY drop that more than offset the core-margin gain and is the primary reason PAT declined YoY even as revenue fell only modestly. The effective tax rate was steady at roughly 24%, similar to a year ago. No exceptional items appear in this quarter or in either comparator quarter, so this is a clean, unadjusted YoY comparison with no one-off to strip out.

The stock went into the print at ₹1,045, up 17.2% over the past month of trading.

For context: PAT has now risen for 2 consecutive quarters.

The QoQ jump in PAT (+139.9%) is largely a base effect — Q4 FY26 PAT was unusually low at ₹12.28 Cr — and should not be read as a change in trend; the YoY comparison, where both revenue and profit declined, is the more telling read here per our convention. No analyst/street estimates for this quarter were found in a web search (a small-cap print without visible sell-side coverage), so vsStreet is unknown rather than a graded miss. Management's guidance from the Q4 FY26 call — ₹200-300 Cr capex over 2-3 years, a targeted 1-1.5x fixed asset turnover and 15-20% ROI, growth from Performance Solutions/contract manufacturing/YP derivatives, and a planned H2 biocide launch — contained no specific quarterly revenue or margin target, and this filing carries no update on capex progress or the biocide launch, so there is no concrete checkpoint to grade this print against; management gives no formal quarterly guidance on record. No separate management press release accompanied this filing.